Assay Methodology Drives Interleukin-17 Heterogeneity in Psoriasis: A Meta-Analysis
DOI:
https://doi.org/10.33854/heme.v8i3.2295Keywords:
biomarker, ELISA, heterogeneity, interleukin-17, psoriasisAbstract
Psoriasis is a chronic immune-mediated skin disorder in which interleukin-17 (IL-17) plays a central role in disease pathogenesis through the TNF-α/IL-23/IL-17 inflammatory axis. Despite broad consensus on IL-17 elevation in psoriasis, reported circulating levels vary markedly across studies, and the contribution of assay methodology to this variability remains underexplored. This systematic review and meta-analysis evaluated circulating IL-17 levels in psoriasis patients compared to healthy controls, with a primary objective of estimating the pooled effect size and a secondary objective of identifying assay methodology as a potential driver of inter-study heterogeneity. A systematic search of PubMed and Scopus identified 26 eligible studies involving 1,466 psoriasis patients and 1,083 healthy controls. The pooled standardised mean difference was 1.22 (95% CI: 0.78 to 1.66, p < 0.001), confirming significantly elevated circulating IL-17 in psoriasis patients. Substantial heterogeneity was observed (I² = 95.31%), prompting comprehensive moderator analysis. Diagnostic tool type (ELISA versus non-ELISA) and study sample size emerged as significant moderators, while geographic region, psoriasis subtype, sex distribution, patient age, and methodological quality score did not significantly contribute to variability. Sensitivity analysis confirmed the robustness of the pooled estimate, and no publication bias was detected. Incomplete reporting of disease severity, treatment history, and disease duration across included studies limited full characterisation of heterogeneity sources. These findings support the role of IL-17 as a biomarker and therapeutic target in psoriasis, and indicate that assay methodology represents a key source of variability in circulating IL-17 measurement. Standardised immunoassay protocols and comprehensive clinical reporting are needed in future primary research to improve the reliability and comparability of IL-17 estimates across studies.References
Sundaresan B, Shirafkan F, Ripperger K, et al. The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses 2023; 15: 782.
Orzan OA, Tutunaru CV, Ianoși SL. Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders. Int J Mol Sci 2025; 26: 749.
Singh S, Kalb RE, de Jong EMGJ, et al. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Am J Clin Dermatol 2018; 19: 879–886.
Chen Y, Wei L, Song Y, et al. Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study. Ann Med; 55: 2231847.
Sieminska I, Pieniawska M, Grzywa TM. The Immunology of Psoriasis—Current Concepts in Pathogenesis. Clin Rev Allergy Immunol 2024; 66: 164–191.
McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity 2019; 50: 892–906.
Man A-M, Orăsan MS, Hoteiuc O-A, et al. Inflammation and Psoriasis: A Comprehensive Review. Int J Mol Sci 2023; 24: 16095.
Chhabra S, Dogra S, Sharma K, et al. Recent Update on Immunopathogenesis of Psoriasis. Indian J Dermatol 2022; 67: 360–373.
Brembilla NC, Senra L, Boehncke W-H. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol 2018; 9: 1682.
Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol 2018; 201: 1605–1613.
Berry SPD-G, Dossou C, Kashif A, et al. The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases. Int Immunopharmacol 2022; 102: 108402.
Morsy H, Hasaballa A, Awad S. Interleukin-17 levels in patients with psoriasis with or without metabolic syndrome. J Egypt Womens Dermatol Soc 2019; 16: 164.
Sobhan M, Ghasemi Basir HR, Seif Rabiee MA, et al. Serum level of interleukin-17 in patients with psoriasis. Immunopathol Persa 2022; 1.
Oliveira PSSD, Cardoso PRG, Lima EVDA, et al. IL‐17A, IL‐22, IL‐6, and IL‐21 Serum Levels in Plaque‐Type Psoriasis in Brazilian Patients. Mediators Inflamm; 2015. Epub ahead of print January 2015. DOI: 10.1155/2015/819149.
Michalak-Stoma A, Bartosińska J, Kowal M, et al. IL-17A in the Psoriatic Patients’ Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity. Mediators Inflamm 2020; 2020: 7420823.
Hong D, Liu X, Qiu X, et al. Profiling Serum Cytokines and Anticytokine Antibodies in Psoriasis Patients. J Immunol Res 2022; 2022: 2787954.
Yilmaz SB, Cicek N, Coskun M, et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res 2012; 304: 465–469.
Liu X-Q, Zhou P-L, Yin X-Y, et al. Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis. PLOS ONE 2023; 18: e0293327.
Zhou XY, Bao J, Huang B, et al. Association between plasma interleukin-17 levels and risk of psoriasis: a meta-analysis. Clin Exp Dermatol 2017; 42: 161–166.
Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol 2024; 24: 243.
Wang X-Y, Chen X-Y, Li J, et al. MiR-200a expression in CD4+ T cells correlates with the expression of Th17/Treg cells and relevant cytokines in psoriasis vulgaris: A case control study. Biomed Pharmacother 2017; 93: 1158–1164.
Antonatos C, Grafanaki K, Asmenoudi P, et al. Contribution of the Environment, Epigenetic Mechanisms and Non-Coding RNAs in Psoriasis. Biomedicines 2022; 10: 1934.
ten Bergen LL, Petrovic A, Krogh Aarebrot A, et al. The TNF/IL-23/IL-17 axis—Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol 2020; 92: e12946.
Knight V, Long T, Meng QH, et al. Variability in the Laboratory Measurement of Cytokines. Epub ahead of print 1 October 2020. DOI: 10.5858/arpa.2019-0519-CP.
Song F, Khan KS, Dinnes J, et al. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002; 31: 88–95.
Brembilla NC, Boehncke W-H. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol 2023; 14: 1186455.
Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci 2019; 20: 1475.
Arican O, Aral M, Sasmaz S, et al. Serum Levels of TNF‐α, IFN‐γ, IL‐6, IL‐8,IL‐12, IL‐17, and IL‐18 in Patients With Active Psoriasis andCorrelation With Disease Severity. Mediators Inflamm 2005; 2005: 273–279.
Choe YB, Hwang YJ, Hahn HJ, et al. A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis: Inflammatory cytokines and psoriasis phenotype. Br J Dermatol 2012; 167: 762–767.
Kyriakou A, Patsatsi A, Vyzantiadis T-A, et al. Serum Levels of TNF-α, IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity. J Immunol Res 2014; 2014: 467541.
Xuan M, Lu C, Han L, et al. Circulating levels of inflammatory cytokines in patients with psoriasis vulgaris of different Chinese medicine syndromes. Chin J Integr Med 2015; 21: 108–114.
Fotiadou C, Lazaridou E, Sotiriou E, et al. IL-17A, IL-22, and IL-23 as Markers of Psoriasis Activity: A Cross-sectional, Hospital-based Study. J Cutan Med Surg 2015; 19: 555–560.
Roh NK, Han SH, Youn HJ, et al. Tissue and Serum Inflammatory Cytokine Levels in Korean Psoriasis Patients: A Comparison between Plaque and Guttate Psoriasis. Ann Dermatol 2015; 27: 738.
Chhabra S, Narang T, Joshi N, et al. Circulating T-helper 17 cells and associated cytokines in psoriasis. Clin Exp Dermatol 2016; 41: 806–810.
Lesiak A, Bednarski I, Pałczyńska M, et al. Are interleukin-15 and -22 a new pathogenic factor in pustular palmoplantar psoriasis? Adv Dermatol Allergol 2016; 5: 336–339.
Abbas I, Al-Mohana A, Al-Dhalimi M, et al. Cytokine Serum Level Association with Superantigen Production by Staphylococcus aureus in Psoriasis vulgaris. Res J Pharm Biol Chem Sci 2016; 7: 172–180.
Bajaj S, Gautam RK, Khurana A, et al. Effect of narrow band ultraviolet B phototherapy on T helper 17 cell specific cytokines (interleukins-17, 22 and 23) in psoriasis vulgaris. J Dermatol Treat 2017; 28: 14–17.
Zheng Y-Z, Chen C-F, Jia L-Y, et al. Correlation between microRNA-143 in peripheral blood mononuclear cells and disease severity in patients with psoriasis vulgaris. Oncotarget 2017; 8: 51288–51295.
Fouad NA, Akl EM, Ahmed SH. Association of Genetic Variants of the Interleukin- 17F rs763780 and its Circulating Level in Psoriasis Patients in Egypt. Egypt J Immunol 2020; 27(2): 39–46.
El-Komy M, Amin I, El-Hawary MS, et al. Upregulation of the miRNA-155, miRNA-210, and miRNA-20b in psoriasis patients and their relation to IL-17. Int J Immunopathol Pharmacol; 34. Epub ahead of print January 2020. DOI: 10.1177/2058738420933742.
Borsky P, Chmelarova M, Fiala Z, et al. Aging in psoriasis vulgaris: female patients are epigenetically older than healthy controls. Immun Ageing; 18. Epub ahead of print December 2021. DOI: 10.1186/s12979-021-00220-5.
Wang H, Wang S, Li L, et al. Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis. Cytokine 2021; 138: 155391.
Wang Y, Jiang F, Chen F, et al. LncRNA XIST Engages in Psoriasis via Sponging miR-338-5p to Regulate Keratinocyte Proliferation and Inflammation. Skin Pharmacol Physiol 2022; 35: 196–205.
Elbana AM, Elgamal E, Hashim O, et al. Pro‐inflammatory versus anti‐inflammatory cytokines in psoriatic patients (case–control study). J Cosmet Dermatol 2022; 21: 6302–6307.
Nassar AA, Bakr NM, Elyousefi EHI, et al. Serum immunoglobulin E and Interleukin‐17 levels in patients with chronic plaque psoriasis: A CASE–CONTROL study. J Cosmet Dermatol 2022; 21: 6377–6384.
Rajasekharan A, Munisamy M, Menon V, et al. Stress and psoriasis: Exploring the link through the prism of hypothalamo-pituitary-adrenal axis and inflammation. J Psychosom Res 2023; 170: 111350.
Wojciechowska M, Ścibior K, Betyna-Białek M, et al. The Unknown Role of Periostin in Psoriatic Epidermal Hyperplasia. Int J Mol Sci 2023; 24: 16295.
Ganeva M, Tsokeva Z, Gancheva T, et al. Serum concentrations of 25-OH vitamin D and the pro-inflammatory interleukins IL-17, IL-23, and IL-18 in patients with plaque psoriasis. Biomed Pap 2024; 168: 124–131.
Wang Q, Yan D, Zheng S, et al. Cytokine Profiles and the Relationship of Disease Severity in Patients with Psoriasis. Indian J Dermatol 2022; 67: 204.
Florian T-L, Florian I-A, Vesa SC, et al. Inflammatory Cytokines and Clinical Outcome Following Biological Therapy in Adult Bio-Naïve Psoriasis Patients. Curr Issues Mol Biol 2024; 46: 7719–7729.
Shaikh MA, Haque Z, Haque A, et al. Protein targets & therapeutics in psoriasis: toward personalization. Int Immunopharmacol 2025; 164: 115331.
Kruczek W, Frątczak A, Litwińska-Inglot I, et al. Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland. J Clin Med 2025; 14: 5421.
McInnes IB, Coates LC, Mease PJ, et al. Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. Nat Med 2025; 31: 4160–4171.
AlMutairi N, Eassa BI. Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature. Adv Dermatol Allergol Dermatol Alergol 2021; 38: 281–288.
Demirel Öğüt N, Ayanoğlu MA, Koç Yıldırım S, et al. Are IL-17 inhibitors superior to IL-23 inhibitors in reducing systemic inflammation in moderate-to-severe plaque psoriasis? A retrospective cohort study. Arch Dermatol Res 2025; 317: 232.
Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol 2018; 27: 115–123.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Monica Afrilya Putri , Ariel Pradipta , Windy Keumala Budianti, Lieka Nugrahi Jaslindo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-NC-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
